• J Dansereau, A K Joshi, M E Helewa, T A Doran, I R Lange, E R Luther, D Farine, M L Schulz, G L Horbay, P Griffin, and W Wassenaar.
• British Columbia Women's Hospital, University of British Columbia, Vancouver, British Columbia.
• Am. J. Obstet. Gynecol. 1999 Mar 1;180(3 Pt 1):670-6.

ObjectiveThe goal of this study was to compare carbetocin, a long-acting oxytocin analog, with oxytocin in the prevention of uterine atony after cesarean section.Study DesignWe enrolled 694 patients undergoing elective cesarean section in a Canadian multicenter, double-blind, randomized clinical trial. We compared the effect of a single 100 microg dose of carbetocin with that of a standard 8-hour infusion of oxytocin. The primary outcome was the proportion of patients requiring additional oxytocic intervention for uterine atony. A variable sample size, sequential design was used.ResultsThe overall oxytocic intervention rate was 7.4%. The odds of treatment failure requiring oxytocic intervention was 2.03 (95% confidence interval 1.1 to 2.8) times higher in the oxytocin group compared with the carbetocin group, respectively, 32 of 318 (10.1%) versus 15 of 317 (4.7%), P <.05.ConclusionsCarbetocin, a new drug for the prevention of uterine atony, appears to be more effective than a continuous infusion of oxytocin and has a similar safety profile.

This article appears in the collection: Carbetocin at Cesarean Section.

19 keywords...

hide…